Boman, Kurt

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Riesmeyer, J. S., Riddle, M. C., Rydén, L., et al. (2019) · The Lancet

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 3,163

Intensive Lipid Lowering with Simvastatin and Ezetimibe in Aortic Stenosis

Rossebø, A. B., Pedersen, T. R., Boman, K., Brudi, P., Chambers, J. B., Egstrup, K., Gerdts, E., Gohlke-Bärwolf, C., Holme, I., Kesäniemi, Y. A., et al. (2008) · New England Journal of Medicine

Lipoproteins and Cardiovascular HealthCardiac Valve Diseases and Treatments

Cited by 1,644

Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial

Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Botros, F. T., Riddle, M. C., Rydén, L., et al. (2019) · The Lancet

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 638

High Plasminogen Activator Inhibitor and Tissue Plasminogen Activator Levels in Plasma Precede a First Acute Myocardial Infarction in Both Men and Women: Evidence for the Fibrinolytic System as an Independent Primary Risk Factor

Thögersen, A. M., Jansson, J.-H., Boman, K., Nilsson, T. K., Weinehall, L., Huhtasaari, F., & Hallmans, G. (1998) · Circulation

Blood Coagulation and Thrombosis MechanismsAcute Myocardial Infarction Research

Cited by 602

The Västerbotten Intervention Programme: background, design and implications

Norberg, M., Wall, S., Boman, K., & Weinehall, L. (2010) · Global Health Action

Health Promotion and Cardiovascular PreventionHealthcare Systems and Public Health

Cited by 373

Effects of person-centred and integrated chronic heart failure and palliative home care. PREFER: a randomized controlled study

Brännström, M., & Boman, K. (2014) · European Journal of Heart Failure

Palliative Care and End-of-Life IssuesHeart Failure Treatment and Management

Cited by 356

Hypertension in Aortic Stenosis: Implications for Left Ventricular Structure and Cardiovascular Events

Rieck, Å. E., Cramariuc, D., Boman, K., Gohlke-Bärwolf, C., Staal, E. M., Lønnebakken, M. T., Rossebø, A. B., & Gerdts, E. (2012) · Hypertension

Cardiac Valve Diseases and TreatmentsBlood Pressure and Hypertension Studies

Cited by 129

Contribution of Swedish moist snuff to the metabolic syndrome: A wolf in sheep's clothing?

Norberg, M., Stenlund, H., Lindahl, B., Boman, K., & Weinehall, L. (2006) · Scandinavian Journal of Public Health

Smoking Behavior and CessationDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 70

Activities of daily living for old persons in primary health care with chronic heart failure

Norberg, E., Boman, K., & Löfgren, B. (2008) · Scandinavian Journal of Caring Sciences

Heart Failure Treatment and ManagementAging, Health, and Disability

Cited by 67

Fatigue and health-related quality of life in elderly patients with and without heart failure in primary healthcare

Hägglund, L., Boman, K., Olofsson, M., & Brulin, C. (2007) · European Journal of Cardiovascular Nursing

Heart Failure Treatment and ManagementCardiac Health and Mental Health

Cited by 50

Effect modifications of lipid-lowering therapy on progression of aortic stenosis (from the Simvastatin and Ezetimibe in Aortic Stenosis [SEAS] Study)

Greve, A. M., Bang, C. N., Boman, K., Egstrup, K., Forman, J. L., Kesäniemi, Y. A., Ray, S., Pedersen, T. R., Best, P., Rajamannan, N. M., et al. (2018) · The American Journal of Cardiology

Cardiac Valve Diseases and TreatmentsLipoproteins and Cardiovascular Health

Cited by 34